Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature.
Interleukin-6
Rheumatoid arthritis
Systemic sclerosis
Tocilizumab
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
07
2018
accepted:
25
03
2019
entrez:
4
5
2019
pubmed:
3
5
2019
medline:
3
5
2019
Statut:
epublish
Résumé
The details of two rheumatoid arthritis (RA) patients with systemic sclerosis (SSc) who were administered tocilizumab, an anti-interleukin-6 receptor antibody, are reported, along with a review of the literature. Two RA patients with SSc with inadequate responses to disease-modifying antirheumatic drugs (DMARDs) were given tocilizumab 162 mg every 2 weeks for 18 months. RA disease activity was evaluated by the 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR) and the clinical disease activity index (CDAI). The skin condition of SSc was evaluated by pinching the skin according to the modified Rodnan total skin thickness score (mRSS). Softening of the skin and improvements of arthritis and the patient global assessment were observed during tocilizumab treatment, with reduction of not only RA disease activity, but also of the mRSS. Tocilizumab may be effective in patients with RA and SSc overlap syndrome for which conventional treatment is inadequate. Further research is needed because this report included only two patients.
Sections du résumé
BACKGROUND
BACKGROUND
The details of two rheumatoid arthritis (RA) patients with systemic sclerosis (SSc) who were administered tocilizumab, an anti-interleukin-6 receptor antibody, are reported, along with a review of the literature.
CASE PRESENTATION
METHODS
Two RA patients with SSc with inadequate responses to disease-modifying antirheumatic drugs (DMARDs) were given tocilizumab 162 mg every 2 weeks for 18 months. RA disease activity was evaluated by the 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR) and the clinical disease activity index (CDAI). The skin condition of SSc was evaluated by pinching the skin according to the modified Rodnan total skin thickness score (mRSS). Softening of the skin and improvements of arthritis and the patient global assessment were observed during tocilizumab treatment, with reduction of not only RA disease activity, but also of the mRSS.
CONCLUSION
CONCLUSIONS
Tocilizumab may be effective in patients with RA and SSc overlap syndrome for which conventional treatment is inadequate. Further research is needed because this report included only two patients.
Identifiants
pubmed: 31049490
doi: 10.1186/s41927-019-0063-x
pii: 63
pmc: PMC6480678
doi:
Types de publication
Case Reports
Langues
eng
Pagination
15Déclaration de conflit d'intérêts
Ethics approval to publish a case report is not needed from our institute (Mie University Graduate School of Medicine).The authors obtained written consent from both patients for the publication of the data.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Rheumatology (Oxford). 2010 Dec;49(12):2408-12
pubmed: 20819796
J Rheumatol. 2012 Jun;39(6):1120-4
pubmed: 22505699
Ann Rheum Dis. 2012 Jul;71(7):1235-42
pubmed: 22586157
Ann Rheum Dis. 2013 Apr;72(4):583-9
pubmed: 23144446
Ann Rheum Dis. 2013 Jul;72(7):1217-20
pubmed: 23253926
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Mod Rheumatol. 2015 Jan;25(1):134-7
pubmed: 24533556
Case Rep Rheumatol. 2014;2014:386328
pubmed: 24839573
Rheumatology (Oxford). 2015 Feb;54(2):371-2
pubmed: 25480809
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S3-14
pubmed: 26243174
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S179-81
pubmed: 26339896
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S3-7
pubmed: 26457375
Lancet. 2016 Jun 25;387(10038):2630-2640
pubmed: 27156934
Ann Rheum Dis. 2017 Feb;76(2):408-413
pubmed: 27338777
Scand J Rheumatol. 2018 May;47(3):248-250
pubmed: 28480784
Ann Rheum Dis. 2018 Jan;77(1):128-132
pubmed: 29061853
Clin Rheumatol. 2018 Apr;37(4):999-1009
pubmed: 29214548